Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 14, 2016; 22(34): 7645-7659
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
Table 3 Results of studies with molecular targeted therapies as second line in advanced hepatocellular carcinoma
| Treatment | Trial | OS | TTP/PFS | Ref. |
| Brivanib | Brivanib vs placebo (BRISK-PS) | 9.4 mo vs 8.2 mo, P = 0.3307; | 4.2 mo vs 2.7 mo, P < 0.001; | [42] |
| HR = 0.89; 95%CI: 0.69-1.15 | HR = 0.56; 95%CI: 0.42-0.76 | |||
| Everolimus | Everolimus vs placebo (EVOLVE-1) | 7.6 mo vs 7.3 mo, P = 0.68; | 3.0 mo vs 2.6 mo, P = 0.01; | [44] |
| HR = 1.05; 95%CI: 0.86-1.27 | HR = 0.93; 95%CI: 0.75-1.15 | |||
| Ramucirumab | Ramucirumab vs placebo (REACH) | 9.2 mo vs 7.6 mo, P = 0.14; | 2.8 mo vs 2.1 mo, P < 0.0001; | [45] |
| HR = 0.87; 95%CI: 0.72-1.05 | HR = 0.63; 95%CI: 0.52-0.75 |
- Citation: Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659
- URL: https://www.wjgnet.com/1007-9327/full/v22/i34/7645.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i34.7645